| Document |
Document Title |
|
WO/2005/028466A1 |
The invention relates to a group of novel benzimidazolone and quinazolinone derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical composit...
|
|
WO/2005/023831A1 |
The invention relates to detection of cholesterol ozonation products that are generated by atherosclerotic plaque material, and to methods of detecting vascular conditions that relate to the accumulation and oxidation of cholesterol.
|
|
WO/2005/021562A2 |
Compounds of the formulae (I) and (Ia) where X1 is secondary phosphino; R3 is a hydrocarbon radical having from 1 to 20 C atoms, a heterohydrocarbon radical which has from 2 to 20 atoms and at least one heteroatorn selected from the grou...
|
|
WO/2005/019151A1 |
The present invention is directed to a compound of formula I, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator acti...
|
|
WO/2005/019147A2 |
There are described compounds of formula (I) wherein X1 and X2 are each independently of the other fluorine, chlorine or bromine; A1 and A2 are, for example, a bond or a C1-C6alkylene bridge; A3 is a C1-C6alkylene bridge; R1 and R2 are, ...
|
|
WO/2005/016519A1 |
Catalysts including carbon supports having formed thereon compositions which comprise a transition metal carbide, nitride or carbide-nitride are prepared. The catalysts are useful for catalytic oxidation and dehydrogenation reactions, in...
|
|
WO/2005/014519A1 |
The invention relates to a process for the preparation of a substituted geminal difluoroalkane, wherein an oxime is converted to the gerninal difluoroalkane using a nitrite and a complex consisting of HF and an organic base, as well as i...
|
|
WO/2005/011664A1 |
The present invention provides optionally substituted compounds of the formula (I) or salts thereof; wherein R1 is O or S when double bonded to the ring or is OH, SH, or a protected equivalent, when single bonded to the ring, R2 is hydro...
|
|
WO/2005/009613A1 |
An oxidation catalyst for oxidizing a reaction substrate with molecular oxygen, characterized by comprising at least one member selected from the group consisting of specific hydrazyl radicals (e.g., 2,2-diphenyl-1-picrylhydrazyl) and sp...
|
|
WO/2005/007611A2 |
The invention is directed to a process for the preparation of [4(S,R)-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalene-1
-ylidene]-methyl-amine of the Formula (I) by reacting 4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)naphthalene-l-one of...
|
|
WO/2005/007622A2 |
[PROBLEMS] To provide (1) an optically active quaternary ammonium salt which, when used as an asymmetric-axis-containing spiro type phase-transfer catalyst for the asymmetric alkylation of a glycine derivative, shows high stereoselectivi...
|
|
WO/2005/000233A2 |
The present invention is directed to compounds having the structure (I) wherein R1, R2, R3, R4, R5 and m are as defined herein. The compounds of this invention are novel therapeutic agents for the treatment of cancer, metabolic diseases ...
|
|
WO/2004/113273A1 |
Compounds of formula (I), wherein A0, A1, and A2 are each independently of the others a bond or a Cl-C6alkylene bridge; A3 is a Cl-C6alkylene bridge which is unsubstituted or substituted by from one to six identical or different substitu...
|
|
WO/2004/110977A1 |
A process for producing an optically active, 1-alkyl-substituted 2,2,2-trifluoroethylamine represented by the formula [3] (wherein R represents C1-6 alkyl and * indicates asymmetric carbon) or a salt of the compound. These compounds are ...
|
|
WO/2004/108857A1 |
An organic electroluminescent device, which has a pair of electrodes and at least one organic layer including a luminescent layer between the pair of electrodes, wherein at least one layer between the pair of electrodes comprises at leas...
|
|
WO/2004/103941A2 |
This invention provides estrogen receptor modulators having the structure (I) where R1-R5 are as defined in the specification; or a pharmaceutically acceptable salt thereof.
|
|
WO/2004/101496A1 |
The invention relates to a method of creating a carbon-heteroatom bond and, preferably, a carbon-nitrogen bond, by reacting a leaving group-bearing unsaturated compound and a nucleophilic compound. In particular, the invention relates to...
|
|
WO/2004/099122A2 |
This invention provides estrogen receptor modulators having the structure formula (I): wherein R1 to R6 and R8 are as defined in the specification; or a pharmaceutically acceptable salt thereof.
|
|
WO/2004/098582A2 |
The present invention pertains to certain ketones and reduced ketones and derivatives thereof which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption, and more particularly to compounds ...
|
|
WO/2004/096755A1 |
A platinum complex represented by the following formula (1) or (2): wherein the ring A, ring B, ring C, ring D and ring G independently represent an aromatic ring optionally having a substituent or an aromatic heteroring optionally havin...
|
|
WO/2004/093207A2 |
The invention relates to novel mixtures consisting of at least two substances, one substance being used as a matrix material and the other as a material which is capable of emission and contains at least one element having an atomic numb...
|
|
WO/2004/087641A1 |
A compound represented by the general formula (I), a salt thereof, or a solvate of either. (I) (In the formula, R1 means hydrogen, optionally substituted aryl, optionally substituted, (un) saturated, 5- to 7-membered, heterocyclic group,...
|
|
WO/2004/080947A1 |
A compound represented by the following general formula (I), its salt, its solvate or its N-oxide or prodrugs thereof: (I) wherein R1 and R2 represent each an optionally substituted cyclic group, etc.; W is a spacer having from 1 to 6 ca...
|
|
WO/2004/080377A2 |
This invention relates to compounds of the general formula (I) useful as modulators of the KCNQ channel, to pharmaceutical compositions comprising these compounds, and to methods of treatment herewith.
|
|
WO/2004/078702A1 |
The invention relates to a process for the preparation of an &agr -amino carbonyl compound by reacting an imine starting material with a suitable electrophile in the presence of a base. This process has the advantage that the imine start...
|
|
WO/2004/078924A2 |
The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding...
|
|
WO/2004/075885A1 |
The invention relates to novel isotetracenone derivatives, medicaments which contain said derivatives or the salts thereof and the use of the isotetracenone derivatives in the treatment of diseases, especially helicobacter pylori infecti...
|
|
WO/2004/074242A2 |
Compounds of the formula (I) or (II) wherein R1 is C1-C10haloalkylsulfonyl, halobenzenesulfonyl, C2-C10haloalkanoyl, halobenzoyl; R2 is halogen or C1-C10haloalkyl; Arl is phenyl, biphenylyl, fluorenyl, naphthyl, anthracyl, phenanthryl, o...
|
|
WO/2004/074236A1 |
A novel imino compound is synthesized by mixing and reacting ascochlorin, its analog or its derivative with a compound having a primary amino group in the presence/absence of a basic catalyst. The novel imino compound thus synthesized is...
|
|
WO/2004/071442A2 |
The present invention relates to bicyclic derivatives, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of d...
|
|
WO/2004/071401A2 |
A compound having the following formula (I): wherein R1 is lower alkyl optionally substituted with one or more suitable substituent(s); aryl optionally substituted with one or more suitable substituent(s); or fused ring, R2 is acylamino ...
|
|
WO/2004/069900A2 |
Novel monoamidine, monoamidoxime and bisamidine curatives, co-curatives and cure accelerators are provided for use with perfluoroelastomeric compositions as well as novel synthesis methods for making monoamidine- and monoamidoxime-based ...
|
|
WO/2004/067497A1 |
The invention relates to a process for treating an organic solution comprising cyclohexanone oxime, cyclohexanone and an organic solvent, said process comprising distilling the organic solution such as to obtain (i) a first product compr...
|
|
WO/2004/065302A2 |
This invention relates to a novel crystal form of the 1:1 manganese (III) complex of N,N',N'tris[salicylideneaminoethyl]amine, a process for its preparation and the use thereof.
|
|
WO/2004/063148A1 |
The present invention relates to a compound of the formula ((I): in which: n is an integer chosen from 1, 2 and 3; Y represents O; N-OR9, in which R9 represents H or a saturated hydrocarbon-based aliphatic group; CR10R11, in which R10 an...
|
|
WO/2004/062601A2 |
Antibacterial compounds of formula (I) are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infectio...
|
|
WO/2004/058747A1 |
The present invention provides compounds capable of binding to an Fc receptor and modulating Fc receptor activity comprising a core lipophilic group in the form of an Aryl ring substituted with a group rich in p-electrons. The invention ...
|
|
WO/2004/058683A2 |
Compounds which have utility in the treatment of conditions associated with altered mitochondrial function. The compounds having structure (I), including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein X, ...
|
|
WO/2004/056762A2 |
The invention provides novel compounds according to formula (I) relates to compounds with the general formula (I), said compounds being useful, e.g. in the treatment of inflammatory diseases.
|
|
WO/2004/054982A1 |
Disclosed are novel biphenylcarboxamides of formula (I), wherein R, Z, X, Y, m, n, and A have the meanings indicated in the description, several methods for producing said substances, the use thereof for controlling undesired microorgani...
|
|
WO/2004/054954A1 |
A process for the purification of hydroxyaryl aldehydes and ketones comprising the following steps; 1) adding a mineral acid to a first composition comprising a hydroxyaryl aldehyde or a hydroxyaryl ketone; 2) washing the mixture obtaine...
|
|
WO/2004/054961A1 |
A process for the preparation of substituted halogenated anilines from substituted halogenated 1-chlorobenzenes which comprisesa) reacting a substituted halogenated 1-chlorobenzene selectively with an imine in the presence of a transitio...
|
|
WO/2004/053458A2 |
A process is described for producing one or more substituted iminoamines, in particular β-unsaturated β-iminoamines, in a single reaction comprising reacting one or more primary amines, alkynes, and isonitriles in the presence of a t...
|
|
WO/2004/052816A1 |
Compounds of formula (I), wherein A1 and A2 are each independently of the other a bond or a C1-C6alkylene bridge; A3 is a C1-C6alkylene bridge; X1 and X2 are each independently of the other fluorine, chlorine or bromine; Y is O, NR7, S, ...
|
|
WO/2004/052847A2 |
The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula...
|
|
WO/2004/048395A1 |
Novel phosphorescent compound provided through synthesis of an ortho metal complex with the use of easily synthesized ligands. Further, there is provided an electroluminescent element of high luminescence efficiency with the use of the p...
|
|
WO/2004/046087A1 |
Process for the preparation of an enantiomerically enriched Schiff base wherein an amine is contacted with a carbonyl compound wherein the amine and/or the carbonyl compound is a chiral compound, to form a mixture of the enantiomers of t...
|
|
WO/2004/043908A1 |
A process for interconverting a mixture of cis-trans erythro-threo isomers of a compound of formula I into the substantially pure cis isomer. Cis isomers of formula I are usefull intermediates in the synthesis of cis isomers of benzamide...
|
|
WO/2004/043884A2 |
Novel acylating agents useful for preparing activated nucleophiles such as terminally activated polymers are disclosed. In preferred aspects, the acylating agents are formula (I) and formula (II) and they used to prepare activated polyme...
|
|
WO/2004/035551A2 |
The present invention is directed to novel fluorinated dye stabilizers having both high quenching efficiency and solubility in halogenated solvents. These dye stabilizers have shown a significantly effect on improving the dye fastness in...
|
